Wedoany.com Report-Dec.10, Pfizer announced on Tuesday that it has signed an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai Fosun Pharmaceutical, to advance YP05002, an investigational GLP-1 receptor agonist for weight management currently in early clinical development.

Under the agreement, YaoPharma will complete its ongoing Phase I trial, after which Pfizer will assume responsibility for all subsequent development, manufacturing, and global commercialization. Pfizer gains exclusive worldwide rights to the compound.

YaoPharma will receive an upfront payment of $150 million and is eligible for up to $1.94 billion in development, regulatory, and sales milestone payments, plus tiered royalties on future product sales.

Shares of Shanghai Fosun Pharmaceutical, listed in Hong Kong, rose as much as 6.4 percent on Wednesday following the announcement.

The deal expands Pfizer's portfolio in the rapidly growing obesity treatment sector. Last month, Pfizer completed its acquisition of Metsera for up to $10 billion, securing additional clinical-stage assets in the same therapeutic class.

Pfizer had previously discontinued development of two internal oral GLP-1 candidates—lotiglipron in 2023 and danuglipron in 2025—due to safety observations related to liver enzyme elevations. The partnership with YaoPharma provides a new pathway for the company to participate in the expanding market for GLP-1-based weight-management therapies.

The collaboration combines YaoPharma's early research progress with Pfizer's global clinical development expertise and commercial infrastructure, aiming to accelerate the potential availability of an additional treatment option for patients managing obesity and related conditions worldwide.